Long-term follow-up of kidney transplant recipients admitted to a tertiary care transplant center with SARS-CoV-2

Table 4 Risk for all-cause mortality

Covariate	Univariate analyses			Multivariate analyses
	HR	95%CI	P value	HR	95%CI	P value
ICU admission	10.2	4.72-21.9	< 0.001	11.2	5.11-24.5	< 0.001
Age at COVID-19 diagnosis (per year)	1.05	1.02-1.08	0.002	1.06	1.02-1.09	0.001
Male recipient	1.90	0.86-4.17	0.11
Nonwhite recipient	0.60	0.23-1.58	0.31
Diabetes as a cause of ESKD vs other	1.13	0.52-2.50	0.75
Living donor recipient	0.72	0.32-1.64	0.44
Previous transplant	0.66	0.27-1.61	0.36
Tacrolimus + MPA + prednisone maintenance vs other	1.18	0.51-2.78	0.69
Prednisone based immunosuppression	0.87	0.26-2.87	0.82
Treatment of rejection before SARS-CoV-2 infection	--	--	--
Vaccinated	0.81	0.39-1.69	0.58
Baseline eGFR (per mL/m2)	1.0	0.98-1.02	0.94
Interval from transplant to COVID-19 (per month)	1.0	0.99-1.01	0.73
Respiratory symptoms for hospital admission	1.22	0.55-2.68	0.63
Remdesivir for management of COVID	0.48	0.18-1.26	0.14

COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; eGFR: Estimated glomerular filtration rate; ICU: Intensive care unit; ESKD: End-stage kidney disease; MPA: Mycophenolic acid.